{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T21:44:49Z","timestamp":1772142289721,"version":"3.50.1"},"reference-count":49,"publisher":"Japanese Circulation Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2015]]},"DOI":"10.1253\/circj.cj-14-1252","type":"journal-article","created":{"date-parts":[[2015,1,7]],"date-time":"2015-01-07T22:05:26Z","timestamp":1420668326000},"page":"278-284","source":"Crossref","is-referenced-by-count":24,"title":["MicroRNA-33a\/b in Lipid Metabolism"],"prefix":"10.1253","volume":"79","author":[{"given":"Koh","family":"Ono","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Horie","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Nishino","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Baba","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhide","family":"Kuwabara","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Yokode","sequence":"additional","affiliation":[{"name":"Department of Clinical Innovative Medicine, Institute for Advancement of Clinical and Translational Science, Graduate School of Medicine, Kyoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Kita","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. <i>Cell<\/i> 2004; 116: 281\u2013297.","DOI":"10.1016\/S0092-8674(04)00045-5"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Ambros V. The functions of animal microRNAs. <i>Nature<\/i> 2004; 431: 350\u2013355.","DOI":"10.1038\/nature02871"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. <i>Cell<\/i> 1993; 75: 843\u2013854.","DOI":"10.1016\/0092-8674(93)90529-Y"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. <i>Cell<\/i> 1993; 75: 855\u2013862.","DOI":"10.1016\/0092-8674(93)90530-4"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. <i>Cell<\/i> 2005; 120: 15\u201320.","DOI":"10.1016\/j.cell.2004.12.035"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. <i>Genome Res<\/i> 2009; 19: 92\u2013105.","DOI":"10.1101\/gr.082701.108"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kozomara A, Griffiths-Jones S. MiRBase: Integrating microRNA annotation and deep-sequencing data. <i>Nucleic Acids Res<\/i> 2011; 39: D152\u2013D157.","DOI":"10.1093\/nar\/gkq1027"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Cheloufi S, Dos Santos CO, Chong MM, Hannon GJ. A dicer-independent miRNA biogenesis pathway that requires Ago catalysis. <i>Nature<\/i> 2010; 465: 584\u2013589.","DOI":"10.1038\/nature09092"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Rottiers V, Naar AM. MicroRNAs in metabolism and metabolic disorders. <i>Nat Rev Mol Cell Biol<\/i> 2012; 13: 239\u2013250.","DOI":"10.1038\/nrm3313"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Chim SS, Shing TK, Hung EC, Leung TY, Lau TK, Chiu RW, et al. Detection and characterization of placental microRNAs in maternal plasma. <i>Clin Chem<\/i> 2008; 54: 482\u2013490.","DOI":"10.1373\/clinchem.2007.097972"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kuwabara Y, Ono K, Horie T, Nishi H, Nagao K, Kinoshita M, et al. Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage. <i>Circ Cardiovasc Genet<\/i> 2011; 4: 446\u2013454.","DOI":"10.1161\/CIRCGENETICS.110.958975"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Widera C, Gupta SK, Lorenzen JM, Bang C, Bauersachs J, Bethmann K, et al. Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. <i>J Mol Cell Cardiol<\/i> 2011; 51: 872\u2013875.","DOI":"10.1016\/j.yjmcc.2011.07.011"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C, et al. Circulating microRNAs in patients with coronary artery disease. <i>Circ Res<\/i> 2010; 107: 677\u2013684.","DOI":"10.1161\/CIRCRESAHA.109.215566"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Tijsen AJ, Creemers EE, Moerland PD, de Windt LJ, van der Wal AC, Kok WE, et al. Mir423-5p as a circulating biomarker for heart failure. <i>Circ Res<\/i> 2010; 106: 1035\u20131039.","DOI":"10.1161\/CIRCRESAHA.110.218297"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Li S, Zhu J, Zhang W, Chen Y, Zhang K, Popescu LM, et al. Signature microRNA expression profile of essential hypertension and its novel link to human cytomegalovirus infection. <i>Circulation<\/i> 2011; 124: 175\u2013184.","DOI":"10.1161\/CIRCULATIONAHA.110.012237"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Tan KS, Armugam A, Sepramaniam S, Lim KY, Setyowati KD, Wang CW, et al. Expression profile of microRNAs in young stroke patients. <i>PLoS One<\/i> 2009; 4: e7689, doi:10.1371\/journal.pone.0007689.","DOI":"10.1371\/journal.pone.0007689"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Moore KJ, Rayner KJ, Suarez Y, Fernandez-Hernando C. MicroRNAs and cholesterol metabolism. <i>Trends Endocrinol Metab<\/i> 2010; 21: 699\u2013706.","DOI":"10.1016\/j.tem.2010.08.008"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Norata GD, Sala F, Catapano AL, Fernandez-Hernando C. MicroRNAs and lipoproteins: A connection beyond atherosclerosis? <i>Atherosclerosis<\/i> 2013; 227: 209\u2013215.","DOI":"10.1016\/j.atherosclerosis.2012.11.019"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Zhang B, Kawachi E, Matsunaga A, Imaizumi S, Noda K, Uehara Y, et al. Reactivity of direct assays for low-density lipoprotein (LDL) cholesterol toward charge-modified LDL in hypercholesterolemia. <i>Circ J<\/i> 2012; 76: 2241\u20132248.","DOI":"10.1253\/circj.CJ-12-0381"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Cheng AY, Leiter LA. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. <i>Curr Opin Cardiol<\/i> 2006; 21: 400\u2013404.","DOI":"10.1097\/01.hco.0000231412.15049.fb"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. <i>J Am Coll Cardiol<\/i> 2004; 44: 720\u2013732.","DOI":"10.1016\/j.jacc.2004.07.001"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. <i>N Engl J Med<\/i> 2004; 350: 1495\u20131504.","DOI":"10.1056\/NEJMoa040583"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. <i>N Engl J Med<\/i> 2005; 352: 1425\u20131435.","DOI":"10.1056\/NEJMoa050461"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Hirayama A, Honarpour N, Yoshida M, Yamashita S, Huang F, Wasserman SM, et al. Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk: Primary results from the Phase 2 YUKAWA study. <i>Circ J<\/i> 2014; 78: 1073\u20131082.","DOI":"10.1253\/circj.CJ-14-0130"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Zhang B, Kawachi E, Miura S, Uehara Y, Matsunaga A, Kuroki M, et al. Therapeutic approaches to the regulation of metabolism of high-density lipoprotein: Novel HDL-directed pharmacological intervention and exercise. <i>Circ J<\/i> 2013; 77: 2651\u20132663.","DOI":"10.1253\/circj.CJ-12-1584"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Matsue Y, Matsumura A, Suzuki M, Hashimoto Y, Yoshida M. Differences in action of atorvastatin and ezetimibe in lowering low-density lipoprotein cholesterol and effect on endothelial function: Randomized controlled trial. <i>Circ J<\/i> 2013; 77: 1791\u20131798.","DOI":"10.1253\/circj.CJ-13-0033"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Horie T, Ono K, Horiguchi M, Nishi H, Nakamura T, Nagao K, et al. MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo. <i>Proc Natl Acad Sci USA<\/i> 2010; 107: 17321\u201317326.","DOI":"10.1073\/pnas.1008499107"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Horie T, Baba O, Kuwabara Y, Chujo Y, Watanabe S, Kinoshita M, et al. MicroRNA-33 deficiency reduces the progression of atherosclerotic plaque in ApoE<sup>\u2212\/\u2212<\/sup> mice. <i>J Am Heart Assoc<\/i> 2012; 1: e003376, doi:10.1161\/JAHA.112.003376.","DOI":"10.1161\/JAHA.112.003376"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Horie T, Nishino T, Baba O, Kuwabara Y, Nakao T, Nishiga M, et al. MicroRNA-33 regulates sterol regulatory element-binding protein 1 expression in mice. <i>Nat Commun<\/i> 2013; 4: 2883, doi:10.1038\/ncomms3883.","DOI":"10.1038\/ncomms3883"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Horie T, Nishino T, Baba O, Kuwabara Y, Nakao T, Nishiga M, et al. MicroRNA-33b knock-in mice for an intron of sterol regulatory element-binding factor 1 (Srebf1) exhibit reduced HDL-C in vivo. <i>Sci Rep<\/i> 2014; 4: 5312, doi:10.1038\/srep05312.","DOI":"10.1038\/srep05312"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Rayner KJ, Suarez Y, Davalos A, Parathath S, Fitzgerald ML, Tamehiro N, et al. miR-33 contributes to the regulation of cholesterol homeostasis. <i>Science<\/i> 2010; 328: 1570\u20131573.","DOI":"10.1126\/science.1189862"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Najafi-Shoushtari SH, Kristo F, Li Y, Shioda T, Cohen DE, Gerszten RE, et al. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. <i>Science<\/i> 2010; 328: 1566\u20131569.","DOI":"10.1126\/science.1189123"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Marquart TJ, Allen RM, Ory DS, Baldan A. miR-33 links SREBP-2 induction to repression of sterol transporters. <i>Proc Natl Acad Sci USA<\/i> 2010; 107: 12228\u201312232.","DOI":"10.1073\/pnas.1005191107"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Gerin I, Clerbaux LA, Haumont O, Lanthier N, Das AK, Burant CF, et al. Expression of miR-33 from an SREBP2 intron inhibits cholesterol export and fatty acid oxidation. <i>J Biol Chem<\/i> 2010; 285: 33652\u201333661.","DOI":"10.1074\/jbc.M110.152090"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Brown MS, Ye J, Goldstein JL. Medicine: HDL miR-ed down by SREBP introns. <i>Science<\/i> 2010; 328: 1495\u20131496.","DOI":"10.1126\/science.1192409"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Brown MS, Goldstein JL. The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. <i>Cell<\/i> 1997; 89: 331\u2013340.","DOI":"10.1016\/S0092-8674(00)80213-5"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Horton JD, Shimomura I. Sterol regulatory element-binding proteins: Activators of cholesterol and fatty acid biosynthesis. <i>Curr Opin Lipidol<\/i> 1999; 10: 143\u2013150.","DOI":"10.1097\/00041433-199904000-00008"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Horton JD, Goldstein JL, Brown MS. SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. <i>J Clin Invest<\/i> 2002; 109: 1125\u20131131.","DOI":"10.1172\/JCI0215593"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Munehira Y, Ohnishi T, Kawamoto S, Furuya A, Shitara K, Imamura M, et al. Alpha1-syntrophin modulates turnover of ABCA1. <i>J Biol Chem<\/i> 2004; 279: 15091\u201315095.","DOI":"10.1074\/jbc.M313436200"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Allen RM, Marquart TJ, Albert CJ, Suchy FJ, Wang DQ, Ananthanarayanan M, et al. miR-33 controls the expression of biliary transporters, and mediates statin- and diet-induced hepatotoxicity. <i>EMBO Mol Med<\/i> 2012; 4: 882\u2013895.","DOI":"10.1002\/emmm.201201228"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Rayner KJ, Sheedy FJ, Esau CC, Hussain FN, Temel RE, Parathath S, et al. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. <i>J Clin Invest<\/i> 2011; 121: 2921\u20132931.","DOI":"10.1172\/JCI57275"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Tang C, Liu Y, Kessler PS, Vaughan AM, Oram JF. The macrophage cholesterol exporter ABCA1 functions as an anti-inflammatory receptor. <i>J Biol Chem<\/i> 2009; 284: 32336\u201332343.","DOI":"10.1074\/jbc.M109.047472"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Marquart TJ, Wu J, Lusis AJ, Baldan A. Anti-miR-33 therapy does not alter the progression of atherosclerosis in low-density lipoprotein receptor-deficient mice. <i>Arterioscler Thromb Vasc Biol<\/i> 2013; 33: 455\u2013458.","DOI":"10.1161\/ATVBAHA.112.300639"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Rotllan N, Ramirez CM, Aryal B, Esau CC, Fernandez-Hernando C. Therapeutic silencing of microRNA-33 inhibits the progression of atherosclerosis in Ldlr<sup>\u2212\/\u2212<\/sup> mice: Brief report. <i>Arterioscler Thromb Vasc Biol<\/i> 2013; 33: 1973\u20131977.","DOI":"10.1161\/ATVBAHA.113.301732"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Sheng Z, Otani H, Brown MS, Goldstein JL. Independent regulation of sterol regulatory element-binding proteins 1 and 2 in hamster liver. <i>Proc Natl Acad Sci USA<\/i> 1995; 92: 935\u2013938.","DOI":"10.1073\/pnas.92.4.935"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. DeBose-Boyd RA, Ou J, Goldstein JL, Brown MS. Expression of sterol regulatory element-binding protein 1c (SREBP-1c) mRNA in rat hepatoma cells requires endogenous LXR ligands. <i>Proc Natl Acad Sci USA<\/i> 2001; 98: 1477\u20131482.","DOI":"10.1073\/pnas.98.4.1477"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Repa JJ, Liang G, Ou J, Bashmakov Y, Lobaccaro JM, Shimomura I, et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. <i>Genes Dev<\/i> 2000; 14: 2819\u20132830.","DOI":"10.1101\/gad.844900"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Yoshikawa T, Shimano H, Amemiya-Kudo M, Yahagi N, Hasty AH, Matsuzaka T, et al. Identification of liver X receptor-retinoid X receptor as an activator of the sterol regulatory element-binding protein 1c gene promoter. <i>Mol Cell Biol<\/i> 2001; 21: 2991\u20133000.","DOI":"10.1128\/MCB.21.9.2991-3000.2001"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Rottiers V, Obad S, Petri A, McGarrah R, Lindholm MW, Black JC, et al. Pharmacological inhibition of a microRNA family in nonhuman primates by a seed-targeting 8-mer antimiR. <i>Sci Transl Med<\/i> 2013; 5: 212ra162.","DOI":"10.1126\/scitranslmed.3006840"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/79\/2\/79_CJ-14-1252\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T03:15:48Z","timestamp":1498187748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/79\/2\/79_CJ-14-1252\/_article"}},"subtitle":["\u2013 Novel \u201cThrifty\u201d Models \u2013"],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-14-1252","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}